SCHEMBL1034242

SCHEMBL1034242

O=C(Nc1ccncc1)c1cccc2ccc(-c3cccnc3)nc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.54
ATR Q13535 1/20 0.54
ROCK2 O75116 2/20 0.51
ROCK1 Q13464 2/20 0.51
CYP2C9 P11712 3/20 0.51
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
EGLN1 Q9GZT9 1/20 0.50
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
ABL1 P00519 3/20 0.49
BCR P11274 3/20 0.49
SRC P12931 2/20 0.49
PRKCA P17252 2/20 0.49
PRKCD Q05655 1/20 0.49
SIRT2 Q8IXJ6 1/20 0.48
JAK2 O60674 2/20 0.48
PRKCI P41743 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1031934 0.91 EGLN1 (0.60) ALDH1A1CYP2C9NPC1RAB9AEGLN1
SCHEMBL1036245 0.83 ATR (0.58) ALDH1A1ATRCYP2C9EGLN1ABL1
SCHEMBL1034072 0.83 JAK2 (0.51) ALDH1A1EGLN1ABL1SIRT2JAK2
SCHEMBL1034164 0.83 SIRT2 (0.54) ALDH1A1ATRCYP2C9NPC1RAB9A
SCHEMBL1035548 0.83 PARP1 (0.65) ALDH1A1CYP2C9NPC1RAB9AEGLN1
SCHEMBL1034553 0.82 EPHX2 (0.54) ALDH1A1NPC1RAB9AEGLN1SIRT2
SCHEMBL1034842 0.82 SIRT2 (0.51) ALDH1A1ATRCYP2C9NPC1RAB9A
SCHEMBL1031026 0.82 ATR (0.57) ALDH1A1ATRCYP2C9NPC1RAB9A
SCHEMBL1033357 0.81 KMT2A (0.53) ALDH1A1
SCHEMBL1032167 0.81 MEN1 (0.48) ALDH1A1NPC1RAB9AABL1SIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 EP disclosed
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 EP disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
EP-2273992-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-01-19 EP disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 ALDH1A1 2326/4885ATR 1057/4885ROCK2 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.